Lung cancer screening gains highlight stark survival gaps

The gist

Lung cancer screening is climbing nationwide, but glaring state and racial survival gaps show the fight is far from over.

What to know

  • Only 18.3% of 13.3 million eligible U.S. adults got screened for lung cancer in 2024—up from 4.5% in 2015, but still a minority.
  • Five-year survival rates soared to 40.9% in Massachusetts but lagged at just 23.8% in Alabama, with Black individuals' survival trailing at 26.1%.
  • Next-generation genomic testing is fueling calls to modernize access and trial rules as evidence mounts for its impact on advanced lung cancer survival.

Defining the Screening Standard

A decade-old national recommendation set the stage for expanded lung cancer screening, but persistent eligibility limits and referral gaps keep disparities entrenched.

The reimbursement and screening baseline for the November 2026 discussion was set more than a decade earlier: “In 2013, the U.S. Preventive Services Task Force recommended annual low-dose computed tomography (LDCT) screening for adults aged 55–80 with at least 30 pack-years of smoking exposure who currently smoked or had quit within 15 years,” replacing older symptom-driven approaches and creating a national standard. That benchmark is what later November 2026 reporting could measure against when assessing whether screening uptake and survival were improving, and where geographic and racial disparities persisted despite a clearer standard of care.

Baptist Health’s November 12, 2026 explainer showed how that standard translated into the care pathway now being expanded, stressing that “annual low-dose CT screening can detect lung abnormalities early and has been shown to reduce lung cancer deaths” and that “repeat annual scans help physicians spot changes over time.” At the same time, it underscored why disparities remain embedded in the system: screening “may be recommended for people who meet age and smoking-history criteria,” while routine screening is generally not recommended for never-smokers, making access dependent not just on technology and reimbursement but on who is identified, referred, and followed.

Sources

Progress Shadowed by Late Diagnoses

Despite rising screening rates, most lung cancers are still found at an advanced stage—where survival plummets—highlighting the life-or-death impact of early detection.

November 2026 reporting made the lung-cancer story newly visible because it paired stubborn mortality with measurable national progress. Becker’s Hospital Review said plainly that “lung cancer remains the leading cause of cancer death in the U.S.” and that it had “the highest death rate of any cancer, at 27.9 deaths per 100,000 people in 2024,” yet the same snapshot showed screening participation moving upward: in 2024, an estimated 13.3 million U.S. adults were eligible for lung cancer screening, and 18.3% were up to date, versus 4.5% in 2015.

That same November picture also showed why expansion matters clinically, not just operationally. Becker’s Hospital Review reported that “the overall five-year relative survival rate of lung cancer patients diagnosed between 2016 and 2022 was 30%,” while survival remained dramatically stage-dependent: “The five-year relative survival rate… was 10.1% when cancer was diagnosed at a distant stage, compared with 61.2% when cancer was diagnosed at a localized stage,” even though “nearly 44% of lung cancers diagnosed between 2019 and 2023 were found at a distant stage.”

Sources

A Patchwork of Survival Odds

State-by-state and racial divides in lung cancer outcomes reveal that where and who you are still shapes your chances of surviving the disease.

The national improvement in lung cancer outcomes masks a map of sharp inequality. The American Lung Association’s Nov. 16-17, 2026 State of Lung Cancer report, as cited by Becker’s Hospital Review and PR Newswire, said the U.S. five-year survival rate rose from 18.1% in 2018 to 31%, yet state results ranged from 40.9% in Massachusetts to 23.8% in Alabama for patients diagnosed between 2016 and 2022; screening showed the same split, with only 24.4% of eligible people screened nationally and rates spanning 38.7% in Massachusetts to 13.5% in South Dakota.

Those gaps extend beyond geography into who gets diagnosed and treated in time. PR Newswire reported that survival was highest for Asian and Pacific Islander individuals at 35.4% and for white and Latino individuals at 30.8%, but “significantly lower among Black individuals at 26.1%,” while Becker’s Hospital Review said American Indian and Alaska Native patients were at 18.2%; state care patterns were similarly uneven, with early diagnosis ranging from 38.0% in Rhode Island to 21.9% in Hawaii and no-treatment rates from 13.4% in Rhode Island to 36.7% in Nevada.

Sources

Genomics Pushes Policy Overhaul

Breakthroughs in broad genomic testing are forcing regulators to rethink trial designs and coverage rules as precision medicine becomes standard lung cancer care.

Broad genomic testing is moving closer to the center of personalized lung cancer care because the policy and clinical evidence are increasingly aligned. On March 16, 2018, the Centers for Medicare & Medicaid Services issued “a national coverage determination recognizing next-generation sequencing (NGS) as a covered diagnostic laboratory test when specified requirements were met,” a reimbursement shift that reduced uncertainty and helped multigene testing spread, and that foundation now looks more consequential after a new JNCCN study linked broad genomic testing to longer survival in advanced lung cancer.

That survival signal is also giving reform advocates a stronger basis to argue that access barriers and outdated development rules now matter more, not less, as care becomes more biomarker-driven. In the September 2026 analysis, the speaker tied FDA’s revised substantial evidence guidance and a “risk-informed framework for biomarker validation or biomarker qualification” to a modernization path that could make targeted therapies easier to develop and validate, reinforcing pressure for clinical trial designs and access policies that keep pace with broader genomic testing in routine care.

Sources
PR Newswire - General BusinessLife Science Connect

Get the stories behind the trends

Deep-dive reporting and the weekly brief, in your inbox.